The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia

• Muhammad Rauzan,

  Affiliation Cancer and Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore

  ⨯
• Charles T. H. Chuah,

  Affiliations Cancer and Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore, Department of Haematology, Singapore General Hospital, Singapore

  ⨯
• Tun Kiat Ko ,

  * E-mail: tunkiat.ko@duke-nus.edu.sg (TKK); sintiong.ong@duke-nus.edu.sg (STO)

  Affiliation Cancer and Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore

  ⨯
• S. Tiong Ong

  * E-mail: tunkiat.ko@duke-nus.edu.sg (TKK); sintiong.ong@duke-nus.edu.sg (STO)

  Affiliations Cancer and Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore, Department of Haematology, Singapore General Hospital, Singapore, Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America

  ⨯